Sunesis to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the company will present at two upcoming investor conferences.

Daniel Swisher, Chief Executive Officer of Sunesis, will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 2:00 PM Eastern Time at The Sheraton New York Times Square Hotel in New York City.

Eric Bjerkholt, Executive Vice President, Corporate Development and Finance at Sunesis will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 3:30 PM Eastern Time in New York City.

A live webcast of the presentations will be available on the Sunesis website at http://ir.sunesis.com. A replay of each webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, Qinprezo™ (vosaroxin), in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

For additional information on Sunesis, please visit http://www.sunesis.com.

CONTACT: Investor and Media Inquiries:
         David Pitts
         Argot Partners
         212-600-1902

         Eric Bjerkholt
         Sunesis Pharmaceuticals Inc.
         650-266-3717

         Eliza Schleifstein
         Argot Partners
         917-763-8106
         [email protected]

Source: Sunesis Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Desert Gold Announces Non-Brokered Private Placement and CAD $910,000 in Lead Orders
• Cantaloupe, Inc. to Report Third Quarter Fiscal Year 2024 Results on May 9, 2024
• FEMSA Files 2023 SEC Annual Report